CL2015002787A1 - Formulación de acetato de abiraterona. - Google Patents

Formulación de acetato de abiraterona.

Info

Publication number
CL2015002787A1
CL2015002787A1 CL2015002787A CL2015002787A CL2015002787A1 CL 2015002787 A1 CL2015002787 A1 CL 2015002787A1 CL 2015002787 A CL2015002787 A CL 2015002787A CL 2015002787 A CL2015002787 A CL 2015002787A CL 2015002787 A1 CL2015002787 A1 CL 2015002787A1
Authority
CL
Chile
Prior art keywords
abiraterone acetate
composition
formulation
critting
understanding
Prior art date
Application number
CL2015002787A
Other languages
English (en)
Inventor
H William Bosch
Marck Norret
Paul Nemeth
Matt Callahan
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of CL2015002787A1 publication Critical patent/CL2015002787A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C19/00—Other disintegrating devices or methods
    • B02C19/16—Mills provided with vibrators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN METODO PARA PRODUCIR UNA COMPOSICION QUE COMPRENDE NANOPARTICULAS DE ACETATO DE ABIRATERONA COMPRENDIENDO MOLER EN SECO UNA COMPOSICION QUE COMPRENDE ACETATO DE ABIRATERONA, UN COMPUESTO DE TRITURACION, UN AGENTE FACILITADOR Y UNO O AMBOS DE UN ANTIOXIDANTE Y UN SECUESTRANTE EN UN MOLINO, POR UN TIEMPO SUFICIENTE PARA PRODUCIR UNA COMPOSICION QUE COMPRENDE PARTICULAS FINAS DE ACETATO DE ABIRATERONA; COMPOSICION DE DOSIS UNITARIA; Y SU METODO DE PREPARACION.
CL2015002787A 2013-03-15 2015-09-15 Formulación de acetato de abiraterona. CL2015002787A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789141P 2013-03-15 2013-03-15
US201361883941P 2013-09-27 2013-09-27

Publications (1)

Publication Number Publication Date
CL2015002787A1 true CL2015002787A1 (es) 2016-05-13

Family

ID=51538105

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002787A CL2015002787A1 (es) 2013-03-15 2015-09-15 Formulación de acetato de abiraterona.

Country Status (20)

Country Link
US (3) US20140287039A1 (es)
EP (2) EP2969227B1 (es)
JP (4) JP2016514707A (es)
KR (3) KR20160023641A (es)
CN (2) CN110604721B (es)
AU (2) AU2014232508C1 (es)
BR (1) BR112015023629A8 (es)
CA (1) CA2907415C (es)
CL (1) CL2015002787A1 (es)
ES (1) ES2741800T3 (es)
HK (2) HK1219457A1 (es)
IL (1) IL241612B (es)
MX (1) MX2015013247A (es)
NZ (1) NZ712350A (es)
PL (1) PL2969227T3 (es)
RU (1) RU2732136C2 (es)
SG (2) SG11201507681PA (es)
TW (2) TWI686212B (es)
WO (1) WO2014145813A1 (es)
ZA (1) ZA201507209B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771722B1 (en) 2011-10-28 2018-08-22 GX Technology Canada Ltd. Steerable fairing string
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
WO2015086596A1 (en) * 2013-12-12 2015-06-18 Basf Se Solid form of abiraterone acetate
IN2014MU00303A (es) * 2014-01-28 2015-09-11 Cipla Ltd
AU2015317466A1 (en) * 2014-09-18 2017-02-23 Sun Pharma Global Fze Abiraterone acetate formulation and methods of use
CN105616364B (zh) * 2014-11-07 2018-11-02 深圳万乐药业有限公司 醋酸阿比特龙片及其制备方法
PL3226843T3 (pl) 2014-12-05 2021-12-13 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
EP3824908A1 (en) * 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
CN113995755A (zh) 2016-02-04 2022-02-01 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
BR112018016643A2 (pt) 2016-02-16 2018-12-26 Gx Tech Canada Ltd depressor em folha e fita
EP3463377A1 (en) * 2016-06-03 2019-04-10 Aragon Pharmaceuticals, Inc. Anticancer compositions
JP7171698B2 (ja) * 2017-04-07 2022-11-15 エムエイエイ・ラボラトリーズ・インコーポレイテッド 治療剤の溶解性およびバイオアベイラビリティを改善する方法
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
CN111107852A (zh) * 2017-09-22 2020-05-05 分散技术有限责任公司 阿比特龙-环状寡聚体药物制剂及其形成和施用方法
US20210008081A1 (en) * 2018-03-29 2021-01-14 Leiutis Pharmaceuticals Pvt, Ltd Oral liquid formulations of abiraterone
US11811064B2 (en) 2018-07-24 2023-11-07 Camx Power Llc Dry milling additive and process
CN112788950A (zh) 2018-07-31 2021-05-11 微生物公司 用于治疗伤口的铋-硫醇组合物和方法
HU231297B1 (hu) * 2018-07-31 2022-09-28 Richter Gedeon Nyrt Stabil gyógyszerkészítmények és eljárás az előállításukra
WO2020073126A1 (en) 2018-10-09 2020-04-16 Gx Technology Canada Ltd. Modular foil system for towed marine array
CN113473974A (zh) * 2019-01-25 2021-10-01 深圳市药欣生物科技有限公司 药物组合物
AU2020232706A1 (en) 2019-03-06 2021-09-16 Propella Therapeutics, Inc. Abiraterone prodrugs
US20220362264A1 (en) * 2019-03-18 2022-11-17 Dispersol Technologies, Llc. Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
CN113133983B (zh) * 2020-01-20 2023-12-12 鲁南制药集团股份有限公司 一种治疗前列腺癌的药物组合物
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CN112933053B (zh) * 2021-01-29 2022-11-25 中国药科大学 一种醋酸阿比特龙的纳米晶体及其制剂和制备方法
EP4291159A1 (en) 2021-02-15 2023-12-20 Propella Therapeutics, Inc. Abiraterone prodrugs
US11801252B2 (en) * 2021-03-05 2023-10-31 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition
TWI828471B (zh) 2021-12-15 2024-01-01 大陸商湖南慧澤生物醫藥科技有限公司 醋酸阿比特龍的自微乳組合物和應用
KR20240010280A (ko) 2022-07-15 2024-01-23 한미약품 주식회사 아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 약제학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
CN101568330A (zh) * 2006-06-30 2009-10-28 伊休蒂卡有限公司 用于制备纳米粒形式的生物活性化合物的方法
ES2428634T3 (es) * 2006-08-25 2013-11-08 Janssen Oncology, Inc. Composiciones para el tratamiento del cáncer
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
WO2009026257A2 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
MX344838B (es) * 2009-04-24 2017-01-09 Iceutica Pty Ltd Metodo para la produccion de polvos de nanoparticulas y microparticulas comerciales.
CN106727477A (zh) * 2009-04-24 2017-05-31 伊休蒂卡有限公司 双氯芬酸的新剂型
CN105919939A (zh) * 2009-04-24 2016-09-07 伊休蒂卡有限公司 包封的纳米颗粒在工业规模的制备
US20120135048A1 (en) * 2009-04-24 2012-05-31 Iceutica Pty Ltd novel formulation of indomethacin
DK2696848T3 (da) * 2011-04-15 2020-10-12 Janssen Pharmaceutica Nv Frysetørrede nanosuspensioner af lægemiddel
CN103813794A (zh) * 2011-07-18 2014-05-21 拓凯制药公司 用于治疗前列腺癌的新型组合物及方法
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
CN102743393A (zh) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
WO2014083512A1 (en) * 2012-11-28 2014-06-05 Dr. Reddy's Laboratories Limited Process for preparation of abiraterone acetate

Also Published As

Publication number Publication date
KR20160023641A (ko) 2016-03-03
MX2015013247A (es) 2016-11-25
TWI731321B (zh) 2021-06-21
BR112015023629A2 (pt) 2017-07-18
TW201513896A (zh) 2015-04-16
RU2732136C2 (ru) 2020-09-11
JP2018135351A (ja) 2018-08-30
US20140287039A1 (en) 2014-09-25
EP3578266A1 (en) 2019-12-11
AU2014232508B2 (en) 2018-07-12
US20170354665A1 (en) 2017-12-14
ZA201507209B (en) 2016-12-21
NZ712350A (en) 2020-08-28
KR102121404B1 (ko) 2020-06-11
IL241612B (en) 2020-03-31
EP2969227A4 (en) 2016-12-07
EP3578266B1 (en) 2024-06-19
ES2741800T3 (es) 2020-02-12
TW201943408A (zh) 2019-11-16
KR20180021932A (ko) 2018-03-05
SG11201507681PA (en) 2015-10-29
JP2021008521A (ja) 2021-01-28
CN110604721B (zh) 2022-02-08
CN105246598A (zh) 2016-01-13
CN105246598B (zh) 2019-09-13
JP7320485B2 (ja) 2023-08-03
HK1219457A1 (zh) 2017-04-07
US20160067265A1 (en) 2016-03-10
SG10201709400VA (en) 2018-01-30
CN110604721A (zh) 2019-12-24
AU2018241103A1 (en) 2018-10-25
EP2969227B1 (en) 2019-05-08
TWI686212B (zh) 2020-03-01
RU2015144285A (ru) 2017-04-24
JP2016514707A (ja) 2016-05-23
KR20190141270A (ko) 2019-12-23
HK1220162A1 (zh) 2017-04-28
JP2023103410A (ja) 2023-07-26
AU2014232508C1 (en) 2023-01-19
AU2014232508A1 (en) 2015-10-08
BR112015023629A8 (pt) 2023-04-11
PL2969227T3 (pl) 2019-12-31
WO2014145813A1 (en) 2014-09-18
CA2907415C (en) 2022-04-05
AU2018241103B2 (en) 2020-08-13
EP2969227A1 (en) 2016-01-20
CA2907415A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
CL2015002787A1 (es) Formulación de acetato de abiraterona.
IL263175B (en) Microbiota restoration therapy (mrt) compounds and methods of manufacture
CL2016001547A1 (es) Composiciones para el cuidado oral
BR112016013861A2 (pt) conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica
MX2015014431A (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer.
IL240731B (en) An antibody that binds the p19 subunit of il-23, its production process, a pharmaceutical preparation containing it and its use in cancer treatment
EP3046987B8 (en) Use of organophosphorus containing composites for use in well treatment operations
BR112014017481A8 (pt) formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação
NZ711564A (en) Methods of treating colorectal cancer
CL2015002688A1 (es) Composiciones de agente activo retinoide particulado fino en seco, formulaciones tópicas incluyendo el mismo.
CL2015002161A1 (es) Composiciones no acuosas para el cuidado bucal.
EP2941634A4 (en) Dynamic dose reduction in x-ray inspection
GT201500328A (es) Suplemento de hierro
BR112017000022A2 (pt) nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas
CL2016000180A1 (es) Composición antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparación
BR112014030553A2 (pt) uso cosmético, como agente para prevenir e/ou tratar um defeito estético na pele e/ou seus apêndices, método relacionado, composto, e composição dermatológica
BR102015006886B8 (pt) Composição tópicas que compreendem 4-hexilresorcinol e pós e uso
EP2964032A4 (en) COMPOSITIONS AND METHOD FOR THE PRODUCTION OF VIRUSELIC PARTICLES
EA201600412A1 (ru) Способ производства неорганического материала в виде частиц
AR090725A1 (es) Metodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro
HK1245155A1 (zh) 製備去氧腎上腺素樹脂酸鹽顆粒的方法；去氧腎上腺素樹脂酸鹽顆粒；以及去氧腎上腺素樹脂酸鹽顆粒在藥物製劑中的用途
MX2015017796A (es) Preparacion de particulas secas que comprenden mentol.
IL241328A0 (en) Preparations for use in the prevention and treatment of toxic exposure to organophosphates
PH12016501032A1 (en) Oral care compositions with reduced surface staining
BR112015031585A2 (pt) composição farmacêutica